lesogaberan
Small moleculeexperimental
Lesogaberan (AZD-3355) was an experimental drug candidate developed by AstraZeneca for the treatment of gastroesophageal reflux disease (GERD). As a GABAB receptor agonist, it has the same mechanism of action as baclofen, but is anticipated to have fewer of the central nervous system side effects that limit the clinical use of baclofen for the treatment of GERD. — Wikipedia
Clinical trial activity
10 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2006 (NCT00394472)
Timeline
Indications
Mechanism of action
- GABA-B receptor 2AGONIST
GABBR2 agonist
- GABA-B receptor 1AGONIST
GABBR1 agonist
Chemistry & pharmacology
Loading structure…
SMILES
NC[C@@H](F)C[PH](=O)O- Mol. weight
- 141.08 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaLesogaberan ↗
- ChEMBLCHEMBL448343 ↗
Also known as
- azd3355
- azd3355
- azd3355
- azd 3355
- azd-3355
- azd-3355
- azd-3355
- lesogaberan
- lesogaberan
- lesogaberan
- lesogaberan
- lesogaberan
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02818309 | Phase 2 | Jan 1, 2015 | Government of Taiwan, National Taiwan University |
| NCT01043185 | Phase 2 | Dec 1, 2009 | AstraZeneca, Oklahoma Foundation for Digestive Research |
| NCT01005251 | Phase 2 | Oct 1, 2009 | AstraZeneca, University of North Carolina at Chapel Hill |
| NCT00863161 | Phase 1 | Mar 1, 2009 | AstraZeneca, IQVIA |
| NCT00757419 | Phase 1 | Sep 1, 2008 | AstraZeneca |
| NCT00703534 | Phase 2 | May 1, 2008 | AstraZeneca, University of Wisconsin |
| NCT00688402 | Phase 1 | Apr 1, 2008 | AstraZeneca |
| NCT00684190 | Phase 1 | Mar 1, 2008 | AstraZeneca, IQVIA |
| NCT00743444 | Phase 2 | Feb 1, 2007 | AstraZeneca |
| NCT00394472 | Phase 2 | Nov 1, 2006 | AstraZeneca, University of Amsterdam |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 9 | 9 | 2 | 2006 |
| IQVIA | For profit | 2 | 0 | 1 | 2008 |
| Government of Taiwan | Government | 1 | 0 | 1 | 2015 |
| National Taiwan University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Oklahoma Foundation for Digestive Research | Academic/Hospital | 1 | 0 | 1 | 2009 |
| University of Amsterdam | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 1 | 0 | 1 | 2009 |
| University of Wisconsin | Academic/Hospital | 1 | 0 | 1 | 2008 |
8 organizations
Page 1 / 1